Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Phase 2 investigational data in metabolic dysfunction-associated steatotic liver disease (MASLD) cohorts have reported substantial reductions in hepatic fat fraction following exposure to the triagonist (Sanyal et al., 2024)
Na+- and Clcoupled active transport of carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes
52 weeks for SURPASS-3 and -4) or early termination visit were EQ-5D-5L (SURPASS-1 to -5)
Most patients lose on average 12 - 15% body weight combined with dietary and daily physical activity
US$ 28.75
US$ 23.84
US$ 22.26
